(-)-3-(3-methoxyphenoxy)-N-methylmorphinan oxalate | 90791-68-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: (-)-3-(3-methoxyphenoxy)-N-methylmorphinan oxalate
• 英文别名: (1R,9R,10R)-4-(3-methoxyphenoxy)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;oxalic acid
• CAS: 90791-68-7
• 化学式: C₂H₂O₄*C₂₄H₂₉NO₂
• 分子量: 453.535
• InChiKey: VLGKOFSJBNZLLJ-YGICXTQQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.33
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  96.3
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (-)-3-(3-methoxyphenoxy)-N-methylmorphinan oxalate 在 吡啶盐酸盐 作用下， 反应 0.42h， 生成 (-)-3-(m-hydroxy)phenoxy-N-methylmorphinan
  参考文献：
  名称：

  Potential synthetic codeine substitutes: (-)-3-O-aryl-N-methylmorphinans

  摘要：

  A series of novel O-aryl-N-methylmorphinans (7-19) were synthesized by the Ullmann reaction from levorphanol (4) in our search for a synthetic codeine (2) substitute with reduced addition liability. The compounds were evaluated for antinociceptive potency and receptor binding affinity. Among these compounds, (-)-3-phenoxy-N-methylmorphinan (7) is an orally active analgesic comparable in potency to codeine (2), which exhibits decreased physical dependence liability and longer duration of action.

  DOI：

  10.1021/jm00375a024

文献信息

• US4113729A
  申请人：——

  公开号：US4113729A

  公开（公告）日：1978-09-12
• US4163853A
  申请人：——

  公开号：US4163853A

  公开（公告）日：1979-08-07
• USRE30452E
  申请人：——

  公开号：USRE30452E

  公开（公告）日：1980-12-16
• Potential synthetic codeine substitutes: (-)-3-O-aryl-N-methylmorphinans
  作者：Erno Mohacsi、Tom Hayes、Jerry Sepinwall

  DOI：10.1021/jm00375a024

  日期：1984.9

  A series of novel O-aryl-N-methylmorphinans (7-19) were synthesized by the Ullmann reaction from levorphanol (4) in our search for a synthetic codeine (2) substitute with reduced addition liability. The compounds were evaluated for antinociceptive potency and receptor binding affinity. Among these compounds, (-)-3-phenoxy-N-methylmorphinan (7) is an orally active analgesic comparable in potency to codeine (2), which exhibits decreased physical dependence liability and longer duration of action.